Yohei Migiyama
Overview
Explore the profile of Yohei Migiyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akter S, Migiyama Y, Tsutsuki H, Ono K, Hamasaki C, Zhang T, et al.
Microbiol Immunol
. 2021 Jul;
65(10):449-461.
PMID: 34251710
Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen that presents a serious risk to immunosuppressed individuals and other extremely vulnerable patients such as those in intensive care units. The emergence of...
2.
Migiyama Y, Sakata S, Iyama S, Tokunaga K, Saruwatari K, Tomita Y, et al.
Crit Care
. 2021 Feb;
25(1):59.
PMID: 33573691
Background: The bacterial density of Pseudomonas aeruginosa is closely related to its pathogenicity. We evaluated the effect of airway P. aeruginosa density on the clinical course of mechanically ventilated patients...
3.
Migiyama Y, Anai M, Kashiwabara K, Tomita Y, Saeki S, Nakamura K, et al.
J Infect Chemother
. 2018 Apr;
24(10):852-855.
PMID: 29703650
Lung abscess following flexible bronchoscopy is a rare and sometimes fatal iatrogenic complication. Here, we report the first case of a lung abscess caused by multidrug-resistant Capnocytophaga sputigena following bronchoscopy....
4.
Horio Y, Ichiyasu H, Kojima K, Saita N, Migiyama Y, Iriki T, et al.
PLoS One
. 2017 Jul;
12(7):e0180742.
PMID: 28704475
Purpose: Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow obstruction and pulmonary emphysema. Persistent inflammation and remodeling of the lungs and airways result in reduced lung function and...
5.
Ichiyasu H, Horio Y, Masunaga A, Migiyama Y, Sakamoto Y, Jodai T, et al.
Ther Adv Respir Dis
. 2017 May;
11(7):261-275.
PMID: 28554260
Background: Direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) therapy has been approved for sepsis-associated acute respiratory distress syndrome, but its efficacy for other rapidly progressive interstitial pneumonias (RPIPs) is...
6.
Migiyama Y, Hirosako S, Tokunaga K, Migiyama E, Tashiro T, Sagishima K, et al.
Pulm Pharmacol Ther
. 2017 Apr;
45:142-147.
PMID: 28450200
Background: Ventilator-associated pneumonia (VAP) due to Pseudomonas aeruginosa has a high mortality and recurrence rate, especially in patients with acute respiratory distress syndrome (ARDS). Therefore, new therapeutic strategies against severe...
7.
Nagaoka K, Yanagihara K, Harada Y, Yamada K, Migiyama Y, Morinaga Y, et al.
J Infect Chemother
. 2016 Nov;
23(2):69-73.
PMID: 27894820
The presence of common periodontopathic bacteria, the Fusobacterium nucleatum-periodonticum-simiae group, Prevotella intermedia, and Porphyromonas gingivalis was determined from respiratory tract specimens of bacterial pneumonia by real-time PCR using universal and...
8.
Migiyama Y, Yanagihara K, Kaku N, Harada Y, Yamada K, Nagaoka K, et al.
Jpn J Infect Dis
. 2015 Jun;
69(2):91-6.
PMID: 26073727
Pseudomonas aeruginosa bacteremia occurs mainly in immunocompromised patients. However, P. aeruginosa bacteremia in immunocompetent patients has also been reported. The aim of this study was to evaluate the clinical characteristics...
9.
Morinaga Y, Yamano S, Akamatsu N, Kaku N, Nagaoka K, Migiyama Y, et al.
Jpn J Infect Dis
. 2015 Mar;
68(5):376-80.
PMID: 25766607
The prevention and control of methicillin-resistant Staphylococcus aureus (MRSA) are important, particularly in emergency units. The active surveillance of MRSA was prospectively performed at the emergency medical center of Nagasaki...
10.
Kaku N, Yanagihara K, Morinaga Y, Yamada K, Harada Y, Migiyama Y, et al.
Antimicrob Agents Chemother
. 2014 May;
58(7):4131-7.
PMID: 24820080
Linezolid is the first member of the oxazolidinones and is active against drug-resistant Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA). Additionally, linezolid shows an immunomodulatory effect, such as inhibition...